JP5620272B2 - 化粧品において,食品サプリメントとして,または医薬品として用いるための脂質化合物 - Google Patents
化粧品において,食品サプリメントとして,または医薬品として用いるための脂質化合物 Download PDFInfo
- Publication number
- JP5620272B2 JP5620272B2 JP2010533028A JP2010533028A JP5620272B2 JP 5620272 B2 JP5620272 B2 JP 5620272B2 JP 2010533028 A JP2010533028 A JP 2010533028A JP 2010533028 A JP2010533028 A JP 2010533028A JP 5620272 B2 JP5620272 B2 JP 5620272B2
- Authority
- JP
- Japan
- Prior art keywords
- compound
- formula
- lipid
- compound according
- hydrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- -1 Lipid compounds Chemical class 0.000 title claims description 49
- 235000015872 dietary supplement Nutrition 0.000 title claims description 7
- 239000003814 drug Substances 0.000 title claims description 6
- 239000002537 cosmetic Substances 0.000 title claims description 3
- 150000001875 compounds Chemical class 0.000 claims description 53
- 239000000203 mixture Substances 0.000 claims description 35
- 229910052739 hydrogen Inorganic materials 0.000 claims description 24
- 239000001257 hydrogen Substances 0.000 claims description 24
- 150000002632 lipids Chemical class 0.000 claims description 18
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 15
- 150000003839 salts Chemical class 0.000 claims description 7
- 125000000217 alkyl group Chemical group 0.000 claims description 6
- 239000003963 antioxidant agent Substances 0.000 claims description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 6
- 230000003078 antioxidant effect Effects 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 4
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims description 4
- 150000001768 cations Chemical class 0.000 claims description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 3
- 102000004877 Insulin Human genes 0.000 claims description 3
- 108090001061 Insulin Proteins 0.000 claims description 3
- 239000008103 glucose Substances 0.000 claims description 3
- 229940125396 insulin Drugs 0.000 claims description 3
- 210000002966 serum Anatomy 0.000 claims description 3
- 239000012453 solvate Substances 0.000 claims description 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 3
- 239000004475 Arginine Substances 0.000 claims description 2
- 229920001661 Chitosan Polymers 0.000 claims description 2
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 claims description 2
- 206010022489 Insulin Resistance Diseases 0.000 claims description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 2
- 238000008214 LDL Cholesterol Methods 0.000 claims description 2
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 claims description 2
- 108010069201 VLDL Cholesterol Proteins 0.000 claims description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 claims description 2
- 239000008280 blood Substances 0.000 claims description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 2
- 206010012601 diabetes mellitus Diseases 0.000 claims description 2
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 claims description 2
- 150000002500 ions Chemical class 0.000 claims description 2
- 229960003194 meglumine Drugs 0.000 claims description 2
- 230000002093 peripheral effect Effects 0.000 claims description 2
- 229960001295 tocopherol Drugs 0.000 claims description 2
- 229930003799 tocopherol Natural products 0.000 claims description 2
- 235000010384 tocopherol Nutrition 0.000 claims description 2
- 239000011732 tocopherol Substances 0.000 claims description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims description 2
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims 3
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims 2
- 229910052794 bromium Inorganic materials 0.000 claims 2
- 125000001246 bromo group Chemical group Br* 0.000 claims 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims 2
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims 1
- 125000002640 tocopherol group Chemical group 0.000 claims 1
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 24
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 21
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 18
- 238000011282 treatment Methods 0.000 description 13
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 12
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 11
- 125000003342 alkenyl group Chemical group 0.000 description 11
- IPBCWPPBAWQYOO-UHFFFAOYSA-N 2-(tetradecylthio)acetic acid Chemical compound CCCCCCCCCCCCCCSCC(O)=O IPBCWPPBAWQYOO-UHFFFAOYSA-N 0.000 description 10
- 230000002265 prevention Effects 0.000 description 10
- 235000019439 ethyl acetate Nutrition 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 238000005160 1H NMR spectroscopy Methods 0.000 description 8
- 238000003818 flash chromatography Methods 0.000 description 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 235000014113 dietary fatty acids Nutrition 0.000 description 7
- 239000000194 fatty acid Substances 0.000 description 7
- 229930195729 fatty acid Natural products 0.000 description 7
- 150000004665 fatty acids Chemical class 0.000 description 7
- 150000002431 hydrogen Chemical class 0.000 description 7
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 7
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 6
- 239000012298 atmosphere Substances 0.000 description 6
- 239000012267 brine Substances 0.000 description 6
- 229910052799 carbon Inorganic materials 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 6
- 125000000304 alkynyl group Chemical group 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 229910052717 sulfur Inorganic materials 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 150000001298 alcohols Chemical class 0.000 description 4
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 4
- 235000021281 monounsaturated fatty acids Nutrition 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- 229910052711 selenium Inorganic materials 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 229910004298 SiO 2 Inorganic materials 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000012230 colorless oil Substances 0.000 description 3
- 239000012043 crude product Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 3
- 239000000651 prodrug Substances 0.000 description 3
- 229940002612 prodrug Drugs 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 150000004671 saturated fatty acids Chemical class 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 3
- BDAGIHXWWSANSR-UHFFFAOYSA-N Formic acid Chemical compound OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 229910010082 LiAlH Inorganic materials 0.000 description 2
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 2
- 239000012346 acetyl chloride Substances 0.000 description 2
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 2
- 150000001733 carboxylic acid esters Chemical class 0.000 description 2
- 239000013066 combination product Substances 0.000 description 2
- 229940127555 combination product Drugs 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- YAQLSKVCTLCIIE-UHFFFAOYSA-N 2-bromobutyric acid Chemical compound CCC(Br)C(O)=O YAQLSKVCTLCIIE-UHFFFAOYSA-N 0.000 description 1
- RGHQKFQZGLKBCF-UHFFFAOYSA-N 2-bromoethyl acetate Chemical compound CC(=O)OCCBr RGHQKFQZGLKBCF-UHFFFAOYSA-N 0.000 description 1
- HROSXDVULOBNMU-UHFFFAOYSA-N 2-tetradecylsulfanylethanol Chemical compound CCCCCCCCCCCCCCSCCO HROSXDVULOBNMU-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- JBYXPOFIGCOSSB-GOJKSUSPSA-N 9-cis,11-trans-octadecadienoic acid Chemical compound CCCCCC\C=C\C=C/CCCCCCCC(O)=O JBYXPOFIGCOSSB-GOJKSUSPSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010014486 Elevated triglycerides Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010021024 Hypolipidaemia Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- 206010033307 Overweight Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- 229940053200 antiepileptics fatty acid derivative Drugs 0.000 description 1
- 230000006851 antioxidant defense Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- SIPUZPBQZHNSDW-UHFFFAOYSA-N bis(2-methylpropyl)aluminum Chemical compound CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000009084 cardiovascular function Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 229910052681 coesite Inorganic materials 0.000 description 1
- 229940108924 conjugated linoleic acid Drugs 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229910052906 cristobalite Inorganic materials 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 229960005135 eicosapentaenoic acid Drugs 0.000 description 1
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000021323 fish oil Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 208000006575 hypertriglyceridemia Diseases 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 230000004766 neurogenesis Effects 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 229960002969 oleic acid Drugs 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- VVWRJUBEIPHGQF-MDZDMXLPSA-N propan-2-yl (ne)-n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)\N=N\C(=O)OC(C)C VVWRJUBEIPHGQF-MDZDMXLPSA-N 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- KOUKXHPPRFNWPP-UHFFFAOYSA-N pyrazine-2,5-dicarboxylic acid;hydrate Chemical compound O.OC(=O)C1=CN=C(C(O)=O)C=N1 KOUKXHPPRFNWPP-UHFFFAOYSA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 235000003441 saturated fatty acids Nutrition 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 229910052682 stishovite Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 229910052905 tridymite Inorganic materials 0.000 description 1
- MHNHYTDAOYJUEZ-UHFFFAOYSA-N triphenylphosphane Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 MHNHYTDAOYJUEZ-UHFFFAOYSA-N 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 239000004034 viscosity adjusting agent Substances 0.000 description 1
- 230000004382 visual function Effects 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/46—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/06—Preparations for care of the skin for countering cellulitis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/10—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C323/11—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/12—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/92—Oral administration
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Diabetes (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Birds (AREA)
- Polymers & Plastics (AREA)
- Emergency Medicine (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Dermatology (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
Description
R1は,C10−C21アルキル,1−6個の二重結合を有するC10−C21アルケニル,および1−6個の三重結合を有するC10−C21アルキニルから選択され;
R2およびR3は,同じまたは異なり,水素およびC1−C6アルキル基から選択され;XはO,S,SO,SO2,SiまたはSeから選択され;
n=1または3であり;および
P1は,水素,C10−C21アルキル,1−6個の二重結合を有するC10−C21アルケニル,および1−6個の三重結合を有するC10−C21アルキニルから選択され,これらは任意に置換されていてもよく;またはP1は下記で表され:
の脂質化合物,またはその薬学的に許容可能な塩,複合体または溶媒和物に関する。
本発明の1つの目的は,薬学的活性を有する脂質化合物を提供することである。この目的は,式(I):
R1は,C10−C21アルキル,1−6個の二重結合を有するC10−C21アルケニル,および1−6個の三重結合を有するC10−C21アルキニルから選択され;
R2およびR3は,同じまたは異なり,水素およびC1−C6アルキル基から選択され;Xは,O,S,SO,SO2,SiまたはSeから選択され;
n=1または3であり;および
P1は,水素,C10−C21アルキル,1−6個の二重結合を有するC10−C21アルケニル,および1−6個の三重結合を有するC10−C21アルキニルから選択され,これらは任意に置換されていてもよく;またはP1は下記で表され:
で表される脂質化合物,またはその薬学的に許容可能な塩,複合体または溶媒和物により達成される。
4個の二重結合を有するC15アルケニル,例えば,メチレンにより中断された4個の二重結合をZ−コンフィギュレーションで有するC15アルケニル,
3−5個の二重結合を有するC18アルケニル,例えば,メチレンにより中断された5個の二重結合をZコンフィギュレーションで有するC18アルケニル,
メチレンにより中断された5個の二重結合をZ−コンフィギュレーションで有するC20アルケニル,
メチレンにより中断された6個の二重結合をZ−コンフィギュレーションで有するC22アルケニル。
ここで,Zn+は,
末梢インスリン耐性および/または糖尿病性状態の治療および/または予防;
血漿インスリン,血中グルコースおよび/または血清トリグリセリドの低下;
トリグリセリドレベル,LDLコレステロールレベル,および/またはVLDLコレステロールレベルの上昇の予防および/または治療;
高脂血症状態,例えば高トリグリセリド血症の予防および/または治療;
2型糖尿病の治療および/または予防;
ヒトにおける血清HDLレベルの増加;
肥満または体重過多の治療および/または予防;
体重の減少および/または体重増加の予防;
脂肪肝疾患,例えば非アルコール性脂肪肝疾患(NAFLD)の治療および/または予防;
炎症性疾患または状態,例えば乾癬等の慢性炎症性疾患の治療および/または予防;
低脂血症,高血圧症,アテローム性動脈硬化症,癌,慢性関節リウマチ,および脳疾患,例えば,MSおよびアルツハイマー病からなる群より選択される疾病の治療および/または予防。
本発明者らは,テトラデシルチオ酢酸(TTA)の特定のプロドラッグ,またはインビボで代謝されてTTAとなる化合物,特にこれらの化合物のアルコールおよびアルコールのプロドラッグが,顕著に優れた薬学的活性を有することを見いだした。そのような化合物は式(I)で表される。
脂肪酸は,一方の末端(α)にカルボキシル(COOH)基を,他方の末端(ω)に(通常は)メチル基を有する直鎖炭化水素である。化学では,炭素原子の番号付けはα末端から開始する。
の脂質化合物である。
飽和脂肪酸から誘導
R1はC10−C21アルキルである
例1:
R1=C14,n=1
モノ不飽和脂肪酸から誘導
R1は1個の二重結合を有するC10−C21アルケニルである
例2:
R1=C18,n=1
R1=C14,n=1,X=S
ポリ不飽和脂肪酸から誘導
R1は1−6個の二重結合を有するC10−C22アルケニルである
例4:
R1=メチレンにより中断された5個の二重結合をZ−コンフィギュレーションで有するC20,n=1,X=S
R1=メチレンにより中断された6個の二重結合をZ−コンフィギュレーションで有するC22,n=1
R1=メチレンにより中断された3個の二重結合をZ−コンフィギュレーションで有するC18,n=1
R1=メチレンにより中断された4個の二重結合をZ−コンフィギュレーションで有するC15,n=1
R1=4個の二重結合を有するC15,n=1
R1=メチレンにより中断された5個の二重結合をZ−コンフィギュレーションで有するC18,n=1
R1=5個の二重結合を有するC18,n=1
1−6個の三重結合を含む脂質から誘導
例11:
R1=1個の三重結合を有するC18,n=1
一般式(I)の化合物は,下記の一般的手順により製造することができる。
方法1:
下記の実施例においては,構造はNMRにより確認した。NMRスペクトルは,CDCl3中で記録した。J値はHzで示される。
実施例1:2−テトラデシルスルファニル−エタノール
1H−NMR(200MHz,CDCl3):δ0.85(t,3H),1.23−1.49(m,22H),1.55(m,2H),2.48(t,2H),2.69(t,2H),3.68(t,2H)
MS(ESI):297[M+Na+]+
1H−NMR(200MHz,CDCl3):δ0.85(t,3H),1.23−1.49(m,22H),1.49−1.60(m,2H),2.04(s,3H),2.53(t,2H),2.71(t,2H),4.19(t,2H);
MS(ESI):317[M+H+]+,339[M+Na+]+
工程1:エチル(5E,9Z,12Z,15Z,18Z)−3−チア−ヘンエイコサ−ペンタノアート:
1H−NMR(200MHz,CDCl3):δ0.95(t,3H),1.27(t,3H),1.98−2.19(m,6H),2.76−2.90(m,6H),3.13(s,2H),3.18(d,2H),4,16(q,2H),5.22−5.50(m,9H),5.53−5.71(m,1H);
MS(ESI):385[M+Na+]+
1H−NMR(200MHz,CDCl3):δ0.96(t,3H),1.98−2.12(m,7H),2.66(t,2H),2.76−2.85(m,6H),3.08(d,2H),3.67(q,2H),5.26−5.56(m,10H);
MS(ESI):343[M+Na+]+
工程1:(全Z)−エイコサ−5,8,11,14,17−ペンタエン−1−イルチオアセテート
1H−NMR(200MHz,CDCl3):δ0.95(t,3H),1.41−1.63(m,4H),2.05(m,4H),2.30(s,3H),2.76−2.89(m,10H),5.22−5.44(m,10H)
MS(ESI):369[M+Na+]+
1H−NMR(200MHz,CDCl3):δ0.95(t,3H),1.35−1.61(m,4H),2.06(m,4H),2.51(m,2H),2.76−2.85(m,8H),5.23−5.44(m,10H)
1H−NMR(300MHz,CDCl3):δ0.97(t,3H),1.07(t,3H),1.46(m,2H),1.64−1.74(m,3H),1.79(m,1H),2.10(m,4H),2.66(m,2H),2.83(m,8H),3.20(t,1H),5.35−5.42(m,10H)
MS(ESI):389[M−H+]-
1H−NMR(300MHz,CDCl3):δ0.95(t,3H),1.05(t,3H),1.40−1−70(m,6H),2.10(m,4H),2.30(m,1H),2.50(m,2H),2.65−2.75(m,1H),2.75−2.90(m,8H),3.50(m,1H),3.65(m,1H),5.25−5.50(m,10H)
13C−NMR(75MHz,CDCl3):δ12.12,14.66,20.95,25.22,26.03(3シグナル),27.17,29.24,30.02.30.45.51.76,63.86,127.40,128.26,128.43,128.50,128.56,128.94,130.04,132.41(3つのシグナルが隠れている)
MS(ESI):399[M+Na+]+
Claims (19)
- 式(I):
R1は,3−6個の二重結合を有するC10−C21アルケニルであり;
R2およびR3は,同じまたは異なり,水素およびC1−C6アルキル基から選択され;
XはSであり;
n=1であり;および
P1は,水素である]
で表される脂質化合物,またはその薬学的に許容可能な塩,複合体または溶媒和物。 - R1はメチレンにより中断された3−6個の二重結合をZコンフィギュレーションで有するC10−C21アルケニルである,請求項1記載の脂質化合物。
- 前記脂質化合物の前記塩は,Li+,Na+,K+,NH4+,メグルミン,トリス(ヒドロキシメチル)アミノメタン,ジエチルアミン,およびアルギニンから選択される一価のカチオン;Mg2+,Ca2+,エチレンジアミン,およびピペラジンから選択される二価イオン;またはキトサンである多価カチオンを含む,請求項1または2に記載の脂質化合物。
- R2およびR3は水素である,請求項1−3のいずれかに記載の脂質化合物。
- 医薬品として使用するための,請求項1−4のいずれかに記載の脂質化合物。
- 食品サプリメントとして使用するための,請求項1−4のいずれかに記載の脂質化合物。
- 化粧品において用いるための,請求項1−4のいずれかに記載の脂質化合物。
- 請求項1−4のいずれかに記載の脂質化合物を含む食品サプリメント組成物。
- 請求項1−4のいずれかに記載の脂質化合物を含む脂質組成物。
- 前記脂質組成物の少なくとも60重量%が前記脂質化合物から構成される,請求項9記載の脂質組成物。
- 前記脂質組成物の少なくとも80重量%が前記脂質化合物から構成される,請求項10記載の脂質組成物。
- さらに薬学的に許容可能な抗酸化剤を含む,請求項9−11のいずれかに記載の脂質組成物。
- 前記抗酸化剤はトコフェロールである,請求項12記載の脂質組成物。
- 末梢インスリン耐性および/または糖尿病性状態を治療および/または予防するための,請求項1−4のいずれかに記載の脂質化合物。
- 血漿インスリン,血中グルコースおよび/または血清トリグリセリドを低下させるための,請求項1−4のいずれかに記載の脂質化合物。
- トリグリセリドレベル,LDLコレステロールレベル,および/またはVLDLコレステロールレベルの上昇を予防および/または治療するための,請求項1−4のいずれかに記載の脂質化合物。
- 高脂血症状態を予防および/または治療するための,請求項1−4のいずれかに記載の脂質化合物。
- 請求項1−4のいずれかに記載の脂質化合物を製造する方法であって,下記の工程を含む方法:
a) 式(A):R1−OHの化合物を,式(B):R1−BRの化合物に変換し,
b) 式(B)の化合物を,少なくとも式(C)の化合物と反応させて,
- 請求項1−4のいずれかに記載の脂質化合物を製造する方法であって,下記の工程を含む方法:
a) 式(A):R1−OHの化合物を,式(H):R1−SHの化合物に変換し,
b) 式(H)の化合物を,少なくとも式(J)の化合物と反応させて,
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US98669807P | 2007-11-09 | 2007-11-09 | |
US60/986,698 | 2007-11-09 | ||
PCT/NO2008/000391 WO2009061208A1 (en) | 2007-11-09 | 2008-11-06 | Lipid compounds for use in cosmetic products, as food supplement or as a medicament |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2011503057A JP2011503057A (ja) | 2011-01-27 |
JP2011503057A5 JP2011503057A5 (ja) | 2011-12-22 |
JP5620272B2 true JP5620272B2 (ja) | 2014-11-05 |
Family
ID=40625964
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2010533028A Active JP5620272B2 (ja) | 2007-11-09 | 2008-11-06 | 化粧品において,食品サプリメントとして,または医薬品として用いるための脂質化合物 |
Country Status (5)
Country | Link |
---|---|
US (1) | US8741966B2 (ja) |
EP (1) | EP2217224B1 (ja) |
JP (1) | JP5620272B2 (ja) |
ES (1) | ES2733353T3 (ja) |
WO (1) | WO2009061208A1 (ja) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2217224B1 (en) | 2007-11-09 | 2019-05-08 | Basf As | Lipid compounds for use in cosmetic products, as food supplement or as a medicament |
EP2147910A1 (en) * | 2008-07-15 | 2010-01-27 | Pronova BioPharma Norge AS | Novel lipid compounds |
TR201905768T4 (tr) | 2009-05-08 | 2019-05-21 | Basf As | Kardiyovasküler, metabolik ve enflamatuar hastalık alanları ile ilişkili hastalıkların tedavisinde çoklu doymamış yağlı asitleri. |
GB0909643D0 (en) * | 2009-06-04 | 2009-07-22 | Avexxin As | Glomerulonephritis treatment |
GB201014633D0 (en) | 2010-09-02 | 2010-10-13 | Avexxin As | Rheumatoid arthritis treatment |
JP2014505017A (ja) * | 2010-11-05 | 2014-02-27 | プロノヴァ・バイオファーマ・ノルゲ・アーエス | 脂質化合物を用いる処置方法 |
AR094941A1 (es) | 2013-02-28 | 2015-09-09 | Olaf Hustvedt Svein | Una composición que comprende un compuesto lipídico, un triglicérido y un tensioactivo, y métodos para usarla |
JP6784696B2 (ja) | 2015-04-28 | 2020-11-11 | プロノヴァ バイオファーマ ノルゲ エーエス | 硫黄を含有する構造的に強化された脂肪酸の非アルコール性脂肪性肝炎の予防及び/又は治療のための使用 |
GB201604316D0 (en) | 2016-03-14 | 2016-04-27 | Avexxin As | Combination therapy |
EP3515422A1 (en) | 2016-09-21 | 2019-07-31 | Avexxin AS | Pharmaceutical composition |
AU2018381124B2 (en) | 2017-12-06 | 2024-06-27 | Basf As | Fatty acid derivatives for treating non-alcoholic steatohepatitis |
JP7508447B2 (ja) | 2018-05-23 | 2024-07-01 | ノースシー セラピューティクス ベスローテン フェンノートシャップ | 血糖制御を改善し、炎症性腸疾患を処置するための構造修飾脂肪酸 |
EP4267124A1 (en) | 2020-12-22 | 2023-11-01 | Northsea Therapeutics B.V. | Combination therapies comprising oxygen-containing structurally enhanced fatty acids for treatment of non-alcoholic steatohepatitis |
Family Cites Families (71)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2667489A (en) * | 1952-01-02 | 1954-01-26 | Monsanto Chemicals | beta-(tertiary alkylmercapto) n-ethyl quaternary pyridinium and quinolinium derivatives |
US2909554A (en) * | 1956-07-23 | 1959-10-20 | Monsanto Chemicals | Process for the manufacture of (alkylmercapto) alkyl sulfates |
GB1038723A (ja) * | 1962-03-26 | |||
US3940433A (en) * | 1974-06-06 | 1976-02-24 | Lever Brothers Company | Novel 2-(alkylsulfinyl)ethyl sulfates and compositions employing same |
US4040781A (en) * | 1974-06-06 | 1977-08-09 | Lever Brothers Company | Novel 2-(alkylsulfinyl)ethyl sulfates and compositions employing same |
US4032564A (en) | 1974-09-09 | 1977-06-28 | Zoecon Corporation | Esters of cyclopropylalkanols |
GB1523276A (en) * | 1974-09-20 | 1978-08-31 | Lafon Labor | Sulphur-containing amino compounds |
US4009211A (en) * | 1975-07-29 | 1977-02-22 | Gulf Research & Development Company | Beta,beta-dialkylethylmercaptoethoxylate as new compounds |
US4209410A (en) * | 1976-04-28 | 1980-06-24 | Phillips Petroleum Company | Lubricants |
DE2861974D1 (en) * | 1977-11-11 | 1982-09-16 | Ciba Geigy Ag | Pyridine dicarboxylic acid derivatives, their mixtures with metallic stabilisers and their use in stabilising chlorine-containing thermoplasts |
JPS5570841A (en) | 1978-11-24 | 1980-05-28 | Konishiroku Photo Ind Co Ltd | Forming method of dye image |
US4368190A (en) | 1980-04-17 | 1983-01-11 | Merck & Co., Inc. | Immunologically active dipeptidyl 4-O-,6-O-acyl-2-amino-2-deoxy-D-glucose derivatives and methods for their preparation |
DE3164332D1 (en) * | 1980-10-21 | 1984-07-26 | Boehringer Mannheim Gmbh | Phospholipids that contain sulphur, process for their preparation and medicines containing these compounds |
DE3127503A1 (de) * | 1981-07-11 | 1983-02-17 | Boehringer Mannheim Gmbh, 6800 Mannheim | Neue phospholipide, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel |
US4411808A (en) * | 1982-08-04 | 1983-10-25 | Exxon Research & Engineering Co. | Multifunctional additive for power transmission shift fluids |
US4775223A (en) | 1984-09-20 | 1988-10-04 | Canon Kabushiki Kaisha | Lactic acid derivative, liquid crystal composition containing same and liquid crystal device |
CA2010000A1 (en) | 1989-04-07 | 1990-10-07 | Paul B. Merkel | Photographic recording material containing a cyan dye-forming coupler |
JPH0451149A (ja) | 1990-06-19 | 1992-02-19 | Fuji Photo Film Co Ltd | ハロゲン化銀カラー写真感光材料 |
FR2663928B1 (fr) * | 1990-06-27 | 1994-04-08 | Norsolor | Nouveaux composes acryliques soufres, un procede pour leur preparation et leur application a la synthese de nouveaux polymeres. |
EP0487809A1 (en) | 1990-11-28 | 1992-06-03 | Monsanto Europe S.A./N.V. | Rubber compositions having improved processability and improved rubber-vulcanisate properties |
JPH0543529A (ja) | 1991-08-10 | 1993-02-23 | Taisho Pharmaceut Co Ltd | アルカンアミドアンモニウム化合物 |
JP2793458B2 (ja) | 1992-03-19 | 1998-09-03 | 三井化学株式会社 | コネクター用ポリアミド系樹脂組成物およびコネクター |
JP2755279B2 (ja) | 1992-03-19 | 1998-05-20 | 三井化学株式会社 | 熱可塑性樹脂組成物およびその成形体 |
US5312814A (en) * | 1992-12-09 | 1994-05-17 | Bristol-Myers Squibb Co. | α-phosphonocarboxylate squalene synthetase inhibitors |
DE69431596D1 (de) * | 1993-06-10 | 2002-11-28 | Wake Forest University Winston | (phospho)lipide zum bekämpfen einer hepatitis b-infektion |
JP3110918B2 (ja) | 1993-06-18 | 2000-11-20 | 富士写真フイルム株式会社 | ハロゲン化銀写真感光材料 |
DK70295A (da) | 1994-07-01 | 1996-01-02 | Ciba Geigy Ag | Titan- og zirkonium-komplekser af carboxylsyrer som korrosionsinhibitorer |
US7517858B1 (en) * | 1995-06-07 | 2009-04-14 | The Regents Of The University Of California | Prodrugs of pharmaceuticals with improved bioavailability |
FR2741619B1 (fr) | 1995-11-28 | 1998-02-13 | Pf Medicament | Nouveaux derives de 2,3,5-trimethyl-4-hydroxy-anilides, leur preparation et leur application en therapeutique |
JP2000508645A (ja) | 1996-04-12 | 2000-07-11 | ペプテック リミテッド | ポリ不飽和脂肪酸を使用する免疫病の治療方法 |
US6060515A (en) | 1997-01-24 | 2000-05-09 | The Regents Of The University Of California | Treatment of skin conditions by use of PPARα activators |
JPH11180929A (ja) * | 1997-12-19 | 1999-07-06 | Asahi Glass Co Ltd | エステル誘導体 |
FR2786187B1 (fr) | 1998-11-19 | 2001-11-09 | Univ Paris Curie | Composes du type 2-acylamino-2-deoxy-glucono-1,5-lactone, procede d'obtention, compositions les comportant et utilisations |
FR2792312B1 (fr) * | 1999-04-15 | 2001-06-08 | Oreal | Composes (poly)thia-alcynoiques et leurs derives, compositions les comprenant et leur utilisation |
US6723717B1 (en) | 1999-06-01 | 2004-04-20 | The University Of Texas Southwestern Medical Center | Sulfur-containing thyroxane derivatives and their use as hair growth promotors |
WO2000072920A1 (en) | 1999-06-01 | 2000-12-07 | The University Of Texas Southwestern Medical Center | Substituted biaryl ether compounds |
NO328803B1 (no) | 2000-03-03 | 2010-05-18 | Thia Medica | Nye fettsyreanaloger |
UA75083C2 (uk) * | 2000-06-22 | 2006-03-15 | Тераванс, Інк. | Похідні глікопептидфосфонатів |
FR2828487B1 (fr) | 2001-08-09 | 2005-05-27 | Genfit S A | Nouveaux composes derives d'acides gras, preparation et utilisations |
JP2005514437A (ja) | 2001-12-21 | 2005-05-19 | スリーエム イノベイティブ プロパティズ カンパニー | イオン対複合体を含む医薬用エアロゾル製剤 |
GB2383355A (en) | 2001-12-22 | 2003-06-25 | Schlumberger Holdings | An aqueous viscoelastic fluid containing hydrophobically modified polymer and viscoelastic surfactant |
EP1470258B1 (en) | 2002-01-31 | 2013-08-28 | TFL Ledertechnik GmbH | Composition and its use for imparting water repellency to leather or furskins, textiles and other fibrous materials |
CA2493690C (en) | 2002-06-13 | 2011-11-08 | New York University | Synthetic c-glycolipid and its use for treating cancer, infectious diseases and autoimmune diseases |
FR2845991B1 (fr) | 2002-10-16 | 2005-02-04 | Pf Medicament | Derives d'alpha-phenyl acetanilides et leur application en therapeutique humaine |
US8372430B2 (en) | 2002-12-17 | 2013-02-12 | The Procter & Gamble Company | Compositions, methods, and kits useful for the alleviation of gastrointestinal effects |
EP1600438A4 (en) | 2003-02-28 | 2007-05-02 | Kaneka Corp | METHODS FOR PRODUCING OPTICALLY ACTIVE COMPOUNDS COMPRISING SUBSTITUENTS IN POSITION 2 |
DE10326303A1 (de) | 2003-06-11 | 2004-12-30 | Celares Gmbh | Reagenzien zur Modifikation von Biopharmazeutika, deren Herstellung und Anwendung |
WO2005073164A1 (en) | 2004-01-30 | 2005-08-11 | Peplin Biolipids Pty Ltd | Therapeutic and carrier molecules |
JP4563114B2 (ja) | 2004-08-30 | 2010-10-13 | 出光興産株式会社 | 潤滑剤用添加剤 |
EP1856213A2 (en) | 2005-03-08 | 2007-11-21 | CIBA SPECIALTY CHEMICALS HOLDING INC. Patent Departement | Metal oxide nanoparticles coated with specific n-acylaminomethylene phosphonates |
WO2006117664A1 (en) | 2005-05-04 | 2006-11-09 | Pronova Biopharma Norge As | New dha derivatives and their use as medicaments |
US20070167529A1 (en) * | 2006-01-17 | 2007-07-19 | Walton Rebecca A | Antimicrobial compositions for treating fabrics and surfaces |
EP2004169B1 (en) | 2006-04-12 | 2012-08-08 | Unilever PLC | Oral composition comprising a polyunsaturated fatty acid and salicylic acid for obtaining an antiinflammatory effect in skin |
EP1849449A1 (en) | 2006-04-26 | 2007-10-31 | 3M Innovative Properties Company | Filler containing composition and process for production and use thereof |
US7763607B2 (en) * | 2006-04-27 | 2010-07-27 | Solvay Pharmaceuticals Gmbh | Pharmaceutical compositions comprising CBx cannabinoid receptor modulators and potassium channel modulators |
JP2009536659A (ja) | 2006-05-09 | 2009-10-15 | ヘマクエスト・ファーマシューティカルズ,インコーポレーテッド | 血液疾患の治療法 |
WO2008053331A1 (en) | 2006-11-01 | 2008-05-08 | Pronova Biopharma Norge A/S | Alpha-substituted omega-3 lipids that are activators or modulators of the peroxisome proliferators-activated receptor (ppar). |
WO2008053340A1 (en) | 2006-11-03 | 2008-05-08 | Pronova Biopharma Norge As | A combination product comprising at least one lipid substituted in the alpha position and at least one hypoglycemic agent |
CN101225064A (zh) | 2007-01-19 | 2008-07-23 | 上海汇瑞生物科技有限公司 | 一种制备β-硫杂-α-烷基脂肪酸的新方法 |
DE102007017179A1 (de) | 2007-04-12 | 2008-10-23 | Clariant International Ltd. | Verfahren zur Herstellung von Alkylpolyglykolcarbonsäuren und Polyglykoldicarbonsäuren mittels Direktoxidation |
EP2217224B1 (en) | 2007-11-09 | 2019-05-08 | Basf As | Lipid compounds for use in cosmetic products, as food supplement or as a medicament |
WO2009149496A1 (en) | 2008-06-10 | 2009-12-17 | Central Northern Adelaide Health Service | Treatment of diabetes and complications thereof and related disorders |
FR2933006B1 (fr) | 2008-06-27 | 2010-08-20 | Inst Francais Du Petrole | Solution absorbante contenant un inhibiteur de degradation soufre a groupement carboxyle et methode pour limiter la degradation d'une solution absorbante |
JP5688015B2 (ja) | 2008-07-08 | 2015-03-25 | カタバシス ファーマシューティカルズ,インコーポレイテッド | 脂肪酸でアセチル化されたサリチレート及びその使用 |
EP2147910A1 (en) | 2008-07-15 | 2010-01-27 | Pronova BioPharma Norge AS | Novel lipid compounds |
TR201905768T4 (tr) | 2009-05-08 | 2019-05-21 | Basf As | Kardiyovasküler, metabolik ve enflamatuar hastalık alanları ile ilişkili hastalıkların tedavisinde çoklu doymamış yağlı asitleri. |
WO2011028689A1 (en) | 2009-09-01 | 2011-03-10 | Catabasis Pharmaceuticals, Inc. | Fatty acid niacin conjugates and their uses |
WO2011089529A1 (en) | 2010-01-20 | 2011-07-28 | Pronova Biopharma Norge As | Salicylate fatty acid derivatives |
JP2014505017A (ja) | 2010-11-05 | 2014-02-27 | プロノヴァ・バイオファーマ・ノルゲ・アーエス | 脂質化合物を用いる処置方法 |
WO2012115695A1 (en) | 2011-02-25 | 2012-08-30 | Catabasis Pharmaceuticals, Inc. | Bis-fatty acid conjugates and their uses |
WO2013016531A2 (en) | 2011-07-26 | 2013-01-31 | Purdue Research Foundation | Compounds and methods for use in treating neoplasia and cancer |
-
2008
- 2008-11-06 EP EP08846228.8A patent/EP2217224B1/en active Active
- 2008-11-06 WO PCT/NO2008/000391 patent/WO2009061208A1/en active Application Filing
- 2008-11-06 JP JP2010533028A patent/JP5620272B2/ja active Active
- 2008-11-06 ES ES08846228T patent/ES2733353T3/es active Active
- 2008-11-06 US US12/741,890 patent/US8741966B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
US20100280109A1 (en) | 2010-11-04 |
EP2217224B1 (en) | 2019-05-08 |
EP2217224A4 (en) | 2015-10-07 |
ES2733353T3 (es) | 2019-11-28 |
JP2011503057A (ja) | 2011-01-27 |
EP2217224A1 (en) | 2010-08-18 |
US8741966B2 (en) | 2014-06-03 |
WO2009061208A1 (en) | 2009-05-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5620272B2 (ja) | 化粧品において,食品サプリメントとして,または医薬品として用いるための脂質化合物 | |
AU2020205213B2 (en) | Use of derivatives of polyunsaturated fatty acids as medicaments | |
RU2509071C2 (ru) | Новые липидные соединения | |
JP5552313B2 (ja) | 脂質化合物 | |
US20100266681A1 (en) | Fatty acid alcohols | |
JP5552314B2 (ja) | 新規脂質化合物 | |
JP5575651B2 (ja) | 新規のdha誘導体およびその医薬品としての用途 | |
CA2983377C (en) | Use of structurally enhanced fatty acids containing sulphur for preventing and/or treating non-alcoholic steatohepatitis | |
JPH0587497B2 (ja) | ||
RU2331415C2 (ru) | Длинноцепочечные ненасыщенные оксигенированные соединения и их применение в области терапии, косметики и питания | |
JPWO2006123550A1 (ja) | 炎症性疾患予防又は治療剤 | |
BRPI0717972A2 (pt) | Lipídeos de ômega-3 alfa-substituídos que são ativadores ou moduladores do receptor ativado por proliferadores de peroxissoma (ppar) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20111104 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20111104 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20130808 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130813 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140513 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140714 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20140909 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20140918 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5620272 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |